Cite
HARVARD Citation
Yan, L. et al. (2022). Pharmacodynamic modelling and exposure–response assessment of inebilizumab in subjects with neuromyelitis optica spectrum disorders. British journal of clinical pharmacology. 88 (8), pp. 3803-3812. [Online].